摘要
目的探究藤黄健骨胶囊联合塞来昔布胶囊治疗膝骨关节炎(KOA)的临床疗效。方法将98例KOA患者按随机数字表法分为观察组和对照组,每组49例。对照组给予塞来昔布胶囊治疗,观察组联合应用藤黄健骨胶囊治疗,两组疗程均为3个月。比较两组临床疗效,WOMAC评分及Lequesne&Mery评分,血清炎性因子(TNF-α、IL-6)及基质金属蛋白酶(MMP)-3、9水平,记录两组不良反应发生率。结果观察组总有效率为95.92%(47/49),高于对照组的79.59%(39/49)(P<0.05)。治疗后,两组患者WOMAC评分、Lequesne&Mery评分,血清TNF-α、IL-6、MMP-3、MMP-9水平明显低于治疗前(P<0.05),且观察组低于对照组(P<0.05)。两组不良反应发生率相近(P>0.05)。结论藤黄健骨胶囊联合塞来昔布胶囊治疗KOA安全有效。
Objective To explore the clinical efficacy of Tenghuang Jiangu Capsule(藤黄健骨胶囊)combined with Celecoxib Capsule in the treatment of knee osteoarthritis(KOA).Methods Ninety-eight patients with KOA were randomly divided into observation group and control group according to random number table method,with 49 cases in each group.The control group was treated with Celecoxib Capsule and the observation group was treated with Tenghuang Jiangu Capsule additionally.The treatment course in both groups was 3 months.Clinical effects,WOMAC score,Lequesne&Mery score,the serum levels of inflammatory factors(TNF-α,IL-6)and matrix metalloproteinases(MMP-3,MMP-9)were compared,and the incidence of adverse reactions was recorded.Results The total effective rate of observation group was 95.92%(47/49),which was higher than that(79.59%,39/49)in the control group(P<0.05).After treatment,WOMAC score,Lequesne&Mery score,the serum levels of TNF-α,IL-6,MMP-3 and MMP-9 were significantly lower than those before treatment in both groups,and the indexes mentioned-above were lower in the observation group than those in the control group(P<0.05).The incidence of adverse reactions were similar in both groups(P>0.05).Conclusion Tenghuang Jiangu Capsule combined with Celixib Capsule is effective and safe for patients with KOA.
作者
张康
ZHANG Kang(Sanmenxia Hospital of Traditional Chinese Medicine,Sanmenxia 472000,Henan,China)
出处
《辽宁中医杂志》
CAS
2022年第1期95-98,共4页
Liaoning Journal of Traditional Chinese Medicine
关键词
膝关节骨性关节炎
藤黄健骨胶囊
塞来昔布胶囊
疗效
knee osteoarthritis
Tenghuang Jiangu Capsule(藤黄健骨胶囊)
Celecoxib Capsule
clinical effects
